EGFR-vIII downregulated H2AZK4/7AC though the PI3K/AKT-HDAC2 axis to regulate cell cycle progression.

Hongyu ZhaoYunfei WangChao YangJunhu ZhouLin WangKaikai YiYansheng LiQixue WangJin ShiChun-Sheng KangLiang Zeng

Published in: Clinical and translational medicine (2020)

EGFR-vIII mutation downregulates H2AZK4/7AC and H3K27AC, inhibiting USP11 expression though the PI3K/AKT-HDAC1/2 axis. FK228 is an effective and promising treatment for GBM with EGFR-vIII mutation.

Keyphrases

cell cycle
small cell lung cancer
epidermal growth factor receptor
tyrosine kinase
cell proliferation
poor prognosis
histone deacetylase
signaling pathway
binding protein
smoking cessation